Provectus Biopha SEC Filings

Provectus Biopharmaceuticals, Inc. reported an insider financing transaction involving its CEO and director, Edward Pershing. On 12/05/2025, he acquired an 8% unsecured convertible promissory note with an amount of $ 75,000. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $ 2.862 per share, and will automatically convert into that preferred stock twelve months after its issue date as part of the company’s 2025 Financing.

Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under the terms of the Series D-1 Certificate of Designation. This transaction increases the CEO’s potential future equity exposure through layered conversions from debt to preferred stock and then to common shares.

Provectus Biopharmaceuticals, Inc. executive Dominic Rodrigues has filed a Schedule 13D reporting beneficial ownership of 25,220,549 shares of common stock, equal to 5.67% of the company’s outstanding common stock. This ownership includes shares held directly, through a retirement plan, jointly with his spouse, as custodian for children, and a large number of shares issuable from existing derivative securities.

The filing notes 13,378,760 shares of common stock are issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock and 10,764,400 shares are issuable upon exercise of currently exercisable stock options. On December 2, 2025, 5,382,200 of his previously granted stock options vested. Rodrigues acquired these securities for investment purposes and, as Vice-Chairman and President, may influence the issuer’s corporate activities but states he has no specific current plans for major corporate transactions.

Provectus Biopharmaceuticals, Inc. and major holder Edward Pershing report updated ownership in an Amendment No. 2 to Schedule 13D. As of this amendment, Pershing beneficially owns 49,255,894 shares of common stock, representing 10.56% of Provectus’s outstanding common shares. This total includes common stock held directly and through retirement accounts, shares issuable from stock options exercisable within 60 days, and shares issuable upon conversion of Series D-1 Convertible Preferred Stock and secured convertible promissory notes. The filing also notes that from April 2018 to November 26, 2025, Provectus issued Pershing an aggregate principal amount of $7,117,500 in secured convertible promissory notes, and details multiple note purchases in late 2025 under the company’s 2025 Financing.

Provectus Biopharmaceuticals, Inc. reported a Form 4 transaction by its CEO and director, Edward Pershing, involving an 8% unsecured convertible promissory note tied to the company’s 2025 financing. On 11/26/2025, the reporting person acquired a note with principal of $70,000 that is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.

The filing states that the note’s outstanding principal and interest may be converted into Series D-1 Preferred Stock at any time while it is outstanding, and will automatically convert at the same price per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under their terms.

Provectus Biopharmaceuticals, Inc. (PVCT) reported an insider financing transaction by CEO and director Edward Pershing. On 11/20/2025, Pershing acquired an 8% unsecured convertible promissory note with a principal amount of $30,000, convertible into Series D-1 Convertible Preferred Stock at $2.862 per share. This allows voluntary conversion of the note’s outstanding principal and interest into Series D-1 Preferred at that price while the note is outstanding, and it will automatically convert into preferred shares twelve months after the issue date.

Each share of Series D-1 Preferred is convertible into 10 shares of PVCT common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms. The transaction is part of the issuer’s 2025 financing.

Provectus Biopharmaceuticals (PVCT) CEO and director reported acquiring an 8% unsecured convertible promissory note on 11/13/2025. The note’s outstanding principal and interest may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share, and will automatically convert at that price twelve months after the issue date.

Table II lists an underlying amount of 10,483 shares of Series D-1 Preferred. Each Series D-1 Preferred share is convertible into 10 shares of common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.

Provectus Biopharmaceuticals (PVCT) reported Q3 2025 results with continued operating losses and very limited liquidity. Net loss was $1.32 million for the quarter and $4.34 million for the nine months ended September 30, 2025. Cash was $72,479 as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern.

The company used $2.46 million in operating cash flow year‑to‑date and reported a working capital deficit of $6.19 million as of September 30, 2025. To fund operations, Provectus raised $1.525 million in unsecured 2025 convertible notes during the nine months, which bear 8% interest and automatically convert to Series D‑1 Preferred Stock after 12 months at $2.862 per share; each Series D‑1 share is convertible into 10 common shares.

The company also converted prior‑period notes into equity, issuing 869,415 Series D‑1 Preferred shares during the nine months. Common shares outstanding were 420,279,879 as of November 12, 2025. Operating expenses rose, led by general and administrative costs and stock‑based compensation, while grant revenue concluded by mid‑2025.

Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing filed a Form 4 reporting an insider transaction on 11/06/2025. He acquired an 8% unsecured convertible promissory note issued under the company’s 2025 Financing.

The note may be converted into Series D‑1 Convertible Preferred Stock at $2.862 per share, and will automatically convert twelve months after the issue date. The filing lists 12,230 shares of Series D‑1 Preferred as the securities underlying the note. Each Series D‑1 Preferred share is convertible into 10 shares of common stock, and the preferred automatically converts to common on June 26, 2026 unless converted earlier.

Provectus Biopharmaceuticals (PVCT) CEO and Director Edward Pershing reported acquiring an 8% unsecured convertible promissory note with a principal amount of $65,000 on 10/30/2025.

The note is convertible at a price of $2.862 per share into Series D-1 Convertible Preferred Stock, representing 22,712 preferred shares. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred at $2.862 on the date that is twelve months after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.

Following the reported transaction, $1,180,000 of derivative securities were beneficially owned, held directly.